CN105878703A - Medicine composition capable of improving safety of compound lily injection - Google Patents
Medicine composition capable of improving safety of compound lily injection Download PDFInfo
- Publication number
- CN105878703A CN105878703A CN201610353139.3A CN201610353139A CN105878703A CN 105878703 A CN105878703 A CN 105878703A CN 201610353139 A CN201610353139 A CN 201610353139A CN 105878703 A CN105878703 A CN 105878703A
- Authority
- CN
- China
- Prior art keywords
- injection
- bulbus lilii
- extract
- safety
- stearic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine composition capable of improving the safety of a compound lily injection. The medicine composition used for injection is characterized by being mainly prepared from a lily extract, a parslane herb extract, a small centipeda herb extract and dimeric glycerine dipolyhydroxy stearate, wherein every 100ml of solution contains 10-20g of lily extract, 10-20g of parslane herb extract and 1-2g of small centipeda herb extract; the dosage ratio of lily to parslane herb to small centipeda herb is 10 to 10 to 1. The medicine composition has the beneficial effects that the cosolvent with better safety and more obvious solubilization effects is adopted instead of a cosolvent polysorbate 80, which has potential safety hazards and affects the product quality, in the compound lily injection; dimeric glycerine dipolyhydroxy stearate has higher safety and lower dosage than polysorbate 80, thus reducing the occurrence probability and risk of adverse reactions of the medicines and improving the safety of clinical medication.
Description
Technical field
The invention belongs to pharmaceutical technology field, improve the injection of compound recipe Bulbus Lilii in particular it relates to a kind of
The pharmaceutical composition of liquid safety.
Background technology
Compound recipe Bulbus Lilii injection standard is recorded in health drug standard promulgated by the ministries or commissions of the Central Government (Traditional Chinese medicine historical preparation),
Crude drug is Bulbus Lilii, Herba Portulacae, eritrichium pedumculare, belongs to Chinese medicine injection.There is promoting blood circulation to restore menstrual flow,
Effect of stasis-dispelling and pain-killing.It is clinically used for treating dysmenorrhea, amenorrhea, injury from falling down, rheumatic arthralgia etc..
In China in wide clinical application for many years, clinical efficacy obtains compound recipe Bulbus Lilii injection
The favorable comment of doctor and patient.But in recent years, the Reporting of harms day of Chinese medicine injection clinical practice
Become serious, have impact on the development of the Chinese medicine injection with Chinese Medicine characteristic.Domestic expert learns
Person has carried out numerous studies to the untoward reaction of Chinese medicine injection, and its untoward reaction reported by document
Occur and the cosolvent polyoxyethylene sorbitan monoleate (tween of the existence potential safety hazard of addition in Chinese medicine injection
80) there is the biggest relation.Due to Chinese medicine injection complicated component, in storage and high temperature sterilize mistake
Journey easily occurs solute separate out and affect clarity, the problem such as solution ph is decreased obviously, because of
This adds polyoxyethylene sorbitan monoleate (Tween 80) in such injection and makees cosolvent, adds other
The solubilization-aid effect of cosolvent is the most inconspicuous.But polyoxyethylene sorbitan monoleate (Tween 80) is due to process for refining
Immature, easily become sour in storage and autoclaving process, cause impurity content high, it is difficult to
Reach injection standard, polyoxyethylene sorbitan monoleate (Tween 80) inherently have stronger hemolytic and
Anaphylaxis, applies and adds probability and the risk that untoward reaction occurs in injection.It addition,
Chinese medicine injection is asking that sterilizing and storage process itself there is also that solution ph is decreased obviously
Topic, and polyoxyethylene sorbitan monoleate (Tween 80) easily becomes sour, and more accelerates under the pH value of medicinal liquid
Fall.The compound recipe Bulbus Lilii injection of domestic production at present also adds polyoxyethylene sorbitan monoleate (Tween 80)
Make cosolvent, be faced with same problem.
In view of the foregoing, find that safety is more preferable, the more obvious cosolvent of solubilization-aid effect is replaced
The polyoxyethylene sorbitan monoleate (Tween 80) of poor stability is this injection urgent problem.
Summary of the invention
The technical problem to be solved be to provide a kind of safety more preferably, solubilization-aid effect more
Significantly improve the pharmaceutical composition of compound recipe Bulbus Lilii injection safety.
The present invention solves above-mentioned technical problem and be the technical scheme is that a kind of raising compound recipe hundred
Close injection safety pharmaceutical composition, mainly by Bulbus Lilii extract, Herba portulacae extract,
The injection medicine group that eritrichium pedumculare extract and two polyglycereol dimerization hydroxy stearic acid esters are made
Compound, every 100ml solution contains the Bulbus Lilii extract of 10-20g Bulbus Lilii medical material, 10-20g Dens Equi
The Herba portulacae extract of Herba Amaranthi tricoloris medical material, the eritrichium pedumculare extract of 1-2g eritrichium pedumculare medical material, Bulbus Lilii,
Herba Portulacae, the usage ratio of eritrichium pedumculare medical material are 10:10:1.
For the present invention is better achieved, further, described two polyglycereol dimerization hydroxy stearic acids
The consumption of ester is 0.005g～5.0g/100ml.
For the present invention is better achieved, further, described two polyglycereol dimerization hydroxy stearic acids
The consumption of ester is 0.05g～1.0g/100ml.
For the present invention is better achieved, further, described pharmaceutical composition also includes poly-mountain
Pear ester 80, two polyglycereol dimerization hydroxy stearic acid esters are combined by different proportion with polyoxyethylene sorbitan monoleate
Making cosolvent, two polyglycereol dimerization hydroxy stearic acid esters with the usage ratio of polyoxyethylene sorbitan monoleate are
0.005g～5.0g/100ml:0.001g～2.0g/100ml.
For the present invention is better achieved, further, described medicine composition dosage form be injection,
Powder pin or lyophilizing.
The preparation method of the pharmaceutical composition of above-mentioned raising compound recipe Bulbus Lilii injection safety, including
Following step: (1) compound recipe Bulbus Lilii injection raw medicinal material Bulbus Lilii 100g, Herba Portulacae 100g,
Eritrichium pedumculare 100g, cosolvent 2.0g；Described cosolvent is by two polyglycereol dimerization hydroxy stearic acids
Ester forms with polyoxyethylene sorbitan monoleate, and wherein the content of two polyglycereol dimerization hydroxy stearic acid esters is
0.005g～2.0g, surplus is polyoxyethylene sorbitan monoleate；(2) Bulbus Lilii, Herba Portulacae boiling two
Secondary, each 2 hours, collecting decoction, filter, filtrate reduced in volume to relative density be 1.27～
1.30 (80 DEG C), let cool, and add ethanol and make containing amount of alcohol to be 65%, stand overnight, and filter,
Decompression filtrate recycling ethanol to be concentrated into relative density be 1.30 (80 DEG C), adds 3 times amount water,
Being sufficiently stirred for, cold preservation 48 hours, filter, filtrate reduced in volume is about 1.15 to relative density
(80 DEG C), medicinal liquid is standby；Eritrichium pedumculare boiling secondary, each 1 hour, collecting decoction,
Filtering, it is 1.25～1.30 (80 DEG C) that filtrate is concentrated into relative density, lets cool, adds ethanol and make
Being 65% containing amount of alcohol, stand overnight, filtering, filtrate reduced in volume to relative density is 1.20
(80 DEG C), add ethanol and make containing amount of alcohol to be 70%, stand overnight, and filter, and filtrate is concentrated into
Relative density is 1.30 (80 DEG C), adds 3 times amount water, is sufficiently stirred for, cold preservation 48 hours, filter
Crossing, it is 1.15 (80 DEG C) that filtrate is concentrated into relative density, merges with above-mentioned medicinal liquid, adds 2 times
Amount water, is sufficiently stirred for, cold preservation 24 hours, filters, and filtrate adds cosolvent and water for injection
It is configured to 1000ml solution.Stir evenly.(3) with 20% sodium hydroxide solution regulation pH value of solution
It is worth to 6.5-8.5.(4) above-mentioned solution is filtered through microporous filter membrane.(5) fill, sterilizing, i.e.
?.
The present invention, by substantial amounts of experimentation, finds a kind of two polyglycereol dimerization hydroxy stearic acids
Ester (Solutol) it is the preferable substitute products of polyoxyethylene sorbitan monoleate.Two polyglycereol dimerization
Hydroxy stearic acid ester (Solutol) recorded in European Pharmacopoeia (EP5.5), Germany's medicine
Allusion quotation and British Pharmacopoeia, can be used for the solubilizing agent of ejection preparation.The pharmacological toxicology experiment of document report
Data show that its toxicity is significantly lower than polyoxyethylene sorbitan monoleate (Tween 80).Additionally we are by a large amount of
Experimental studies have found that, reach two polyglycereol dimerization hydroxy stearic acid esters during identical solubilization-aid effect
(Solutol) amount ratio polyoxyethylene sorbitan monoleate (Tween 80) low, more improve medicine
The safety of thing.
The pharmacological toxicology experimental data of document report shows two polyglycereol dimerization hydroxy stearic acid esters
(Solutol) safety higher than polyoxyethylene sorbitan monoleate (Tween 80), its toxicity is obvious
Less than polyoxyethylene sorbitan monoleate (Tween 80) (see table 1-3).In compound recipe Bulbus Lilii injection respectively
Use (0.5g/100ml) two polyglycereol dimerization hydroxy stearic acid ester (Solutol of equivalent) and polyoxyethylene sorbitan monoleate (Tween 80), safety experiment comparative study result shows,
Use (0.5g/100ml) two polyglycereol dimerization hydroxy stearic acid ester (Solutol of equivalent) group is equal in terms of hemolytic, zest, anaphylaxis and the toxicity such as reduce blood pressure
Substantially ratio uses polyoxyethylene sorbitan monoleate (Tween 80) to organize low, considerably reduces compound recipe by the present invention
There is probability and the risk of untoward reaction in Bulbus Lilii injection in clinical practice, improves clinical application
Safety.
To sum up, the invention has the beneficial effects as follows: provide a kind of safety more preferably, solubilization-aid effect more
Potential safety hazard is there is and affects product quality in significantly cosolvent in replacing compound recipe Bulbus Lilii injection
Cosolvent polyoxyethylene sorbitan monoleate (Tween 80)；Two polyglycereol dimerization hydroxy stearic acid ester (Solutol) safety higher than polyoxyethylene sorbitan monoleate (Tween 80) and consumption is lower, reduce medicine
The probability of thing generation untoward reaction and risk, improve the safety of clinical application.
Detailed description of the invention
Embodiment 1
Preparation method: Bulbus Lilii, Herba Portulacae boiling secondary, each 2 hours, collecting decoction,
Filtering, filtrate reduced in volume to relative density is 1.27～1.30 (80 DEG C), lets cool, adds second
It is 65% that alcohol makes containing amount of alcohol, stands overnight, and filters, and decompression filtrate recycling ethanol also concentrates
It is 1.30 (80 DEG C) to relative density, adds 3 times amount water, be sufficiently stirred for, cold preservation 48 hours,
Filtering, filtrate reduced in volume to relative density is about 1.15 (80 DEG C), and medicinal liquid is standby；Intestinum Gallus domesticus
Grass boiling secondary, each 1 hour, collecting decoction, filter, filtrate is concentrated into the closeest
Degree is 1.25～1.30 (80 DEG C), lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stood
At night, filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing second
Alcohol amount is 70%, stands overnight, and filters, and it is 1.30 (80 DEG C) that filtrate is concentrated into relative density,
Add 3 times amount water, be sufficiently stirred for, cold preservation 48 hours, filter, filtrate is concentrated into relative density
It is 1.15 (80 DEG C), merges with above-mentioned medicinal liquid, add 2 times amount water, be sufficiently stirred for, cold preservation 24
Hour, filtering, filtrate adds two polyglycereol dimerization hydroxy stearic acid ester (Solutol)
Make cosolvent and water for injection is configured to 1000ml solution.Stir evenly.Molten with 20% sodium hydroxide
Liquid regulation solution ph is to 6.5-8.5.Above-mentioned solution is filtered through microporous filter membrane.Fill, goes out
Bacterium, to obtain final product.
Embodiment 2
Preparation method: Bulbus Lilii, Herba Portulacae boiling secondary, each 2 hours, collecting decoction,
Filtering, filtrate reduced in volume to relative density is 1.27～1.30 (80 DEG C), lets cool, adds second
It is 65% that alcohol makes containing amount of alcohol, stands overnight, and filters, and decompression filtrate recycling ethanol also concentrates
It is 1.30 (80 DEG C) to relative density, adds 3 times amount water, be sufficiently stirred for, cold preservation 48 hours,
Filtering, filtrate reduced in volume to relative density is about 1.15 (80 DEG C), and medicinal liquid is standby；Intestinum Gallus domesticus
Grass boiling secondary, each 1 hour, collecting decoction, filter, filtrate is concentrated into the closeest
Degree is 1.25～1.30 (80 DEG C), lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stood
At night, filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing second
Alcohol amount is 70%, stands overnight, and filters, and it is 1.30 (80 DEG C) that filtrate is concentrated into relative density,
Add 3 times amount water, be sufficiently stirred for, cold preservation 48 hours, filter, filtrate is concentrated into relative density
It is 1.15 (80 DEG C), merges with above-mentioned medicinal liquid, add 2 times amount water, be sufficiently stirred for, cold preservation 24
Hour, filtering, filtrate adds two polyglycereol dimerization hydroxy stearic acid ester (Solutol)
Make cosolvent with tween 80 and water for injection is configured to 1000ml solution.Stir evenly.With 20%
Sodium hydroxide solution regulation solution ph is to 6.5-8.5.Above-mentioned solution is filtered through microporous filter membrane.
Fill, sterilizing, to obtain final product.
Embodiment 3
Preparation method: Bulbus Lilii, Herba Portulacae boiling secondary, each 2 hours, collecting decoction,
Filtering, filtrate reduced in volume to relative density is 1.27～1.30 (80 DEG C), lets cool, adds second
It is 65% that alcohol makes containing amount of alcohol, stands overnight, and filters, and decompression filtrate recycling ethanol also concentrates
It is 1.30 (80 DEG C) to relative density, adds 3 times amount water, be sufficiently stirred for, cold preservation 48 hours,
Filtering, filtrate reduced in volume to relative density is about 1.15 (80 DEG C), and medicinal liquid is standby；Intestinum Gallus domesticus
Grass boiling secondary, each 1 hour, collecting decoction, filter, filtrate is concentrated into the closeest
Degree is 1.25～1.30 (80 DEG C), lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stood
At night, filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing second
Alcohol amount is 70%, stands overnight, and filters, and it is 1.30 (80 DEG C) that filtrate is concentrated into relative density,
Add 3 times amount water, be sufficiently stirred for, cold preservation 48 hours, filter, filtrate is concentrated into relative density
It is 1.15 (80 DEG C), merges with above-mentioned medicinal liquid, add 2 times amount water, be sufficiently stirred for, cold preservation 24
Hour, filtering, filtrate adds two polyglycereol dimerization hydroxy stearic acid ester (Solutol)
Make cosolvent and water for injection is configured to solution.Stir evenly.With 20% sodium hydroxide solution regulation
Solution ph is to 6.5-8.5.Above-mentioned solution is filtered through microporous filter membrane.It is distributed into 1000,
Lyophilization, to obtain final product.
Embodiment 4:
The Bulbus Lilii extract of the present invention, Herba portulacae extract, eritrichium pedumculare extract and two polyglycereol
Dimerization hydroxy stearic acid ester (Solutol) the injection pharmaceutical composition made can
It is achieved through the following technical solutions:
(1) compound recipe Bulbus Lilii injection raw medicinal material Bulbus Lilii 100g, Herba Portulacae 100g, eritrichium pedumculare
100g, two polyglycereol dimerization hydroxy stearic acid ester (Solutol)2.0g；
(2) Bulbus Lilii, Herba Portulacae boiling secondary, each 2 hours, collecting decoction, filter
Crossing, filtrate reduced in volume to relative density is 1.27～1.30 (80 DEG C), lets cool, adds ethanol
Making containing amount of alcohol is 65%, stands overnight, and filters, and decompression filtrate recycling ethanol is also concentrated into
Relative density is 1.30 (80 DEG C), adds 3 times amount water, is sufficiently stirred for, cold preservation 48 hours, filter
Crossing, filtrate reduced in volume to relative density is about 1.15 (80 DEG C), and medicinal liquid is standby；Eritrichium pedumculare
Boiling secondary, each 1 hour, collecting decoction, filter, filtrate is concentrated into relative density
It is 1.25～1.30 (80 DEG C), lets cool, add ethanol and make containing amount of alcohol to be 65%, stand overnight,
Filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing amount of alcohol
Being 70%, stand overnight, filtering, it is 1.30 (80 DEG C) that filtrate is concentrated into relative density, adds
3 times amount water, are sufficiently stirred for, cold preservation 48 hours, filter, and filtrate is concentrated into relative density and is
1.15 (80 DEG C), merge with above-mentioned medicinal liquid, add 2 times amount water, are sufficiently stirred for, and cold preservation 24 is little
Time, filtering, filtrate adds two polyglycereol dimerization hydroxy stearic acid ester (Solutol)
Make cosolvent and water for injection is configured to 1000ml solution.Stir evenly.
(3) by 20% sodium hydroxide solution regulation solution ph to 6.5-8.5.
(4) above-mentioned solution is filtered through microporous filter membrane.
(5) fill, sterilizing, to obtain final product.
In the present invention, cosolvent can be two polyglycereol dimerization hydroxy stearic acid esters, and its consumption is
Arbitrary value in 0.005g～5.0g/100ml, as 0.005g/100ml, 0.01g/100ml,
0.05g/100ml, 1.0g/100ml, 5.0g/100ml etc.；Cosolvent can also be sweet by dimerization
Oil dimerization hydroxy stearic acid ester and polyoxyethylene sorbitan monoleate form, its usage ratio be 0.005g～
5.0g/100ml:0.001g～2.0g/100ml.
After the present invention uses two polyglycereol dimerization hydroxy stearic acid esters as cosolvent, its safety
More preferably, solubilization-aid effect be more obviously better than polyoxyethylene sorbitan monoleate, concrete data see following table:
Table 1 SolutolWith polyoxyethylene sorbitan monoleate (Tween 80) LD50Toxicity test data compare
Table 2 intravenous injection SolutolWith polyoxyethylene sorbitan monoleate (Tween 80) haemolysis afterwards and serum
Histamine levels compares
Table 3 intravenous injection SolutolCompare with polyoxyethylene sorbitan monoleate (Tween 80) blood pressure lowering level afterwards
It addition, the present invention is by experimental studies have found that, in compound recipe Bulbus Lilii injection, reach identical
Solubilization-aid effect time two polyglycereol dimerization hydroxy stearic acid ester (Solutol) consumption
Lower than polyoxyethylene sorbitan monoleate (Tween 80), more improve Drug safety.Medicine group
Two polyglycereol dimerization hydroxy stearic acid ester (Solutol in compound) consumption be
0.005g-5.0g/100ml, preferable amount is 0.05g-1.0g/100ml.Pharmaceutical composition also may be used
Use two polyglycereol dimerization hydroxy stearic acid ester (Solutol) (tell with polyoxyethylene sorbitan monoleate
Temperature 80) combine by different proportion and to make cosolvent to reduce polyoxyethylene sorbitan monoleate (Tween 80) consumption, two
Polyglycereol dimerization hydroxy stearic acid ester (Solutol) and polyoxyethylene sorbitan monoleate (Tween 80)
Usage ratio be 0.005g-5.0g/100ml:0.001g-2.0g/100ml.
Claims (5)
1. the pharmaceutical composition improving compound recipe Bulbus Lilii injection safety, it is characterized in that, the main injection pharmaceutical composition being made up of Bulbus Lilii extract, Herba portulacae extract, eritrichium pedumculare extract and two polyglycereol dimerization hydroxy stearic acid esters, every 100ml solution is containing the Bulbus Lilii extract of 10-20g Bulbus Lilii medical material, the Herba portulacae extract of 10-20g purslane medicinal material, the eritrichium pedumculare extract of 1-2g eritrichium pedumculare medical material, and Bulbus Lilii, Herba Portulacae, the usage ratio of eritrichium pedumculare medical material are 10:10:1.
The pharmaceutical composition of raising compound recipe Bulbus Lilii injection safety the most according to claim 1, it is characterised in that the consumption of described two polyglycereol dimerization hydroxy stearic acid esters is 0.005g～5.0g/100ml.
The pharmaceutical composition of raising compound recipe Bulbus Lilii injection safety the most according to claim 1, it is characterised in that the consumption of described two polyglycereol dimerization hydroxy stearic acid esters is 0.05g～1.0g/100ml.
The pharmaceutical composition of raising compound recipe Bulbus Lilii injection safety the most according to claim 1, it is characterized in that, described pharmaceutical composition also includes polyoxyethylene sorbitan monoleate, two polyglycereol dimerization hydroxy stearic acid esters and polyoxyethylene sorbitan monoleate are combined by different proportion and are made cosolvent, and two polyglycereol dimerization hydroxy stearic acid esters are 0.005g～5.0g/100ml:0.001g～2.0g/100ml with the usage ratio of polyoxyethylene sorbitan monoleate.
5. according to the pharmaceutical composition improving compound recipe Bulbus Lilii injection safety described in claim 1 to 5 any one, it is characterised in that described medicine composition dosage form is injection, powder pin or lyophilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610353139.3A CN105878703A (en) | 2016-05-24 | 2016-05-24 | Medicine composition capable of improving safety of compound lily injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610353139.3A CN105878703A (en) | 2016-05-24 | 2016-05-24 | Medicine composition capable of improving safety of compound lily injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105878703A true CN105878703A (en) | 2016-08-24 |
Family
ID=56716935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610353139.3A Withdrawn CN105878703A (en) | 2016-05-24 | 2016-05-24 | Medicine composition capable of improving safety of compound lily injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878703A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518617A (en) * | 2009-04-02 | 2009-09-02 | 四川升和制药有限公司 | Pharmaceutical composition for improving safety of Shenmai injection and method for preparing same |
-
2016
- 2016-05-24 CN CN201610353139.3A patent/CN105878703A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518617A (en) * | 2009-04-02 | 2009-09-02 | 四川升和制药有限公司 | Pharmaceutical composition for improving safety of Shenmai injection and method for preparing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105079067A (en) | Pharmaceutical composition for improving safety of compound gastrodin injection | |
| CN101518617B (en) | Pharmaceutical composition for improving safety of Shenmai injection and method for preparing same | |
| CN105106111A (en) | Safe medicine composition for compound gastrodin injection and preparation method of safe medicine composition | |
| CN101417105B (en) | Zedoary turmeric oil glucose injection and preparation method thereof | |
| CN105902580A (en) | Preparing method for pharmaceutical composition capable of improving safety of compound ginkgo biloba injection | |
| CN105878703A (en) | Medicine composition capable of improving safety of compound lily injection | |
| CN105410580B (en) | A kind of corn stigma effervescent solid beverage and preparation method thereof | |
| CN105079107A (en) | Medicine composite of honeysuckle hydrochloric acid extract injection and preparation method thereof | |
| CN105943736A (en) | Pharmaceutical composition capable of improving safety of compound manglietia injection | |
| CN105902637A (en) | Medicine composition for improving safety of compound radix ginseng injection | |
| CN105920117A (en) | Pharmaceutical composition capable of improving safety of compound radix polygoni multiflori injection | |
| CN106389319A (en) | Preparation method of pharmaceutical composition capable of improving safety of compound herba andrographis injection | |
| CN106389317A (en) | Preparation method of pharmaceutical composition for improving safety of compound puerarin injection | |
| CN106309923A (en) | Medicine compound for increasing safety of compound sealwort injection | |
| CN105878731A (en) | Pharmaceutical composition capable of improving safety of compound rhizoma polygonati injection | |
| CN105878396A (en) | Pharmaceutical composition capable of improving safety of compound abrus precatorius injection | |
| CN106389322A (en) | Pharmaceutical composition for improving safety of compound Herba Artemisiae Scopariae injection | |
| CN106361814A (en) | Preparation method of pharmaceutical composition for improving safety of compound ginseng injection | |
| CN106389318A (en) | Pharmaceutical composition for improving safety of compound puerarin injection | |
| CN106361793A (en) | Preparation method of pharmaceutical composition for improving safety of compound herba artemisiae scopariae injection solution | |
| CN106309524A (en) | Medicine compound for increasing safety of compound folium ginkgo injection | |
| CN106389320A (en) | Pharmaceutical composition for improving safety of compound saffron injection | |
| CN106361826A (en) | Preparation method of pharmaceutical composition for improving safety of compound radix codonopsis injection solution | |
| CN101897754B (en) | Preparation method of polyethylene glycol 12-hydroxy stearate-containing danshen root medicament injection preparation | |
| CN106361914A (en) | Preparation method of drug composition for improving safety of compound crocus sativus injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160824 |